followed by statistical analysis on logit-transformed [3] , peak-corrected [4] β-values in R [5] using LIMMA [6] (t-statistics) to identify differential methylation between T and NM samples (Δβ: mean β T -mean β NM ). N and AN samples were pooled into one control group (NM) for further analysis, as analysis for differential methylation (LIMMA applied to peak-corrected M-values) revealed highly similar methylation patterns for the two groups. All samples passed the inclusion criteria of a detection P-value <10 -5 . Multi-dimensional scaling analysis was performed using the 10,000 most variable CpG sites across all tissue samples. Correction for multiple testing (adjusted P-value, adj. P) was performed according to the Benjamini-Hochberg procedure [7] .
Differentially methylated CpG sites (DMCs) were defined as CpG sites with Δβ ≥│0.2│ and adj. P<0.05.
Bisulfite sequencing
Bisulfite sequencing (BS) of genomic DNA from prostatic cell lines was performed as previously described [8] .
Briefly, primers (table S13) were designed using MethPrimer [9] . Bisulfite converted DNA was PCR amplified, gel purified and sub-cloned using the TOPO®TA Cloning® Kit for sequencing (Invitrogen). A minimum of 5 colonies were PCR amplified and sequenced using the M13 forward and reverse primers (included in the TOPO cloning kit), followed by manual inspection of C/T status at each CpG site. Results were visualized and analyzed using QUMA [10] .
RNA-seq
A total of 14 T, 6 N, and 6 AN fresh-frozen prostate tissue samples were collected at Dept. of Urology, Aarhus University Hospital, DK (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) . Of these, 6 T samples were also included in a previous RNA-seq study [11] . Total RNA was isolated from tissue samples using the RNeasy Mini Kit (Qiagen) according to manufacturer's instructions, except that at the time of extraction, 1.5x (vol.) 100% EtOH was added to the tissue samples. All included samples had a RIN score >7, according to RNA Pico chip analysis on a 2100 Bioanalyzer (Agilent Technologies). Whole transcriptome, strand-specific RNA-seq libraries for multiplexed paired-end sequencing were prepared using Ribo-Zero Gold and ScriptSeq v2 kit (Epicentre), as previously described [11] .
Di-tagged cDNA was amplified (10 cycles, FailSafe PCR Enzyme (Epicentre)) and purified (Agencourt XP Kit, Beckman Coulter). RNA-seq libraries were combined into 2 nM pooled stocks, denatured and diluted to 10 pM before loading into TruSeq PE v3 flowcells on an Illumina cBot followed by indexed paired-end sequencing (101+7+101 bp) on Illumina HiSeq 2000 using TruSeq SBS Kit v3 chemistry (Illumina). Paired de-multiplexed fastq files were generated using CASAVA software (Illumina).
RNA-seq data handling and statistical analysis: Paired-end RNA-seq reads were mapped to the human genome (hg19) using TopHat [12] with the Bowtie aligner [13] . HTSeq [14] was used to summarize reads per gene of interest with the "union" overlap resolution mode. Differential expression analysis was performed using edgeR [15] with the most complex dispersion found for each gene. Correction for multiple testing (adjusted P-value, adj. P) was performed according to the Benjamini-Hochberg procedure [7] .
External datasets
450K and RNA-seq data sets (297 T, 34 AN) from The Cancer Genome Atlas (TCGA) were downloaded from the TCGA data portal [16, 17] and processed as described above.
Marmal-aid data was downloaded from the Marmal-aid database [18] . Raw beta-values were batch-and peak corrected using ChAMP [19] . 
